<div class="floatDisplay"><div class="table-wrap" id="tbl4">
<table>
<caption tabindex="0">
<span class="label">Table 4</span><span>Statistical analysis of change from baseline in EQ-5D-3L utility and EQ VAS scores (Week 52 data<a href="#title-footnote-tbl4fna" id="back-title-footnote-tbl4fna" class="figureLink"><sup>a</sup></a><span class="crossref-label" style="display: none;"></span>).</span>
</caption>
<tbody>
<tr>
<th scope="col" rowspan="3"></th>
<th scope="col" colspan="3">Overall study population</th>
<th scope="col" colspan="3">ICS subset</th>
<th scope="col" colspan="3">ICS/LABA subset</th>
</tr>
<tr>
<th scope="col" colspan="2">LS mean change from baseline (SE)</th>
<th scope="col" rowspan="2">Difference FF/VI <em>versus</em> UC<br><br>(95% CI)<a href="#title-footnote-tbl4fnb" id="back-title-footnote-tbl4fnb" class="figureLink"><sup>b</sup></a><span class="crossref-label" style="display: none;"></span><br><br>p-value</th>
<th scope="col" colspan="2">LS mean change from baseline (SE)</th>
<th scope="col" rowspan="2">Difference FF/VI <em>versus</em> UC<br><br>(95% CI)<a href="#title-footnote-tbl4fnc" id="back-title-footnote-tbl4fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span><br><br>p-value</th>
<th scope="col" colspan="2">LS mean change from baseline (SE)</th>
<th scope="col" rowspan="2">Difference FF/VI <em>versus</em> UC<br><br>(95% CI)<a href="#title-footnote-tbl4fnc" id="back-title-footnote-tbl4fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span><br><br>p-value</th>
</tr>
<tr>
<th scope="col">FF/VI (n = 2114)</th>
<th scope="col">UC (n = 2119)</th>
<th scope="col">FF/VI (n = 750)</th>
<th scope="col">UC (n = 755)</th>
<th scope="col">FF/VI (n = 1325)</th>
<th scope="col">UC (n = 1325)</th>
</tr>
<tr>
<th scope="row">EQ-5D-3L utility score</th>
<td>n = 1984<br><br>0.0170 (0.00504)</td>
<td>n = 1988<br><br>0.0051 (0.00502)</td>
<td>0.0119 (−0.0017 to 0.0254)<br><br><em>p</em> = .086</td>
<td>n = 696<br><br>0.0124 (0.00768)</td>
<td>n = 711<br><br>−0.0027 (0.00756)</td>
<td>0.0151 (−0.0060 to 0.0361)<br><br><em>p</em> = .161</td>
<td>n = 1252<br><br>0.0193 (0.00655)</td>
<td>n = 1243<br><br>0.0075 (0.00657)</td>
<td>0.0118 (−0.0058 to 0.0295)<br><br><em>p</em> = .189</td>
</tr>
<tr>
<th scope="row">EQ VAS score</th>
<td>n = 1984<br><br>3.0 (0.43)</td>
<td>n = 1988<br><br>1.4 (0.43)</td>
<td>1.6 (0.4–2.7)<br><br><em>p</em> = .007</td>
<td>n = 696<br><br>1.3 (0.70)</td>
<td>n = 711<br><br>−0.4 (0.69)</td>
<td>1.7 (−0.2 to 3.6)<br><br><em>p</em> = .083</td>
<td>n = 1252<br><br>4.0 (0.54)</td>
<td>n = 1243<br><br>2.3 (0.55)</td>
<td>1.7 (0.2–3.2)<br><br><em>p</em> = .024</td>
</tr>
</tbody>
</table>
<a href="javascript:void(0)" class="tableLink" onclick="window.open('/action/showFullTableImage?isHtml=true&amp;tableId=tbl4&amp;pii=S095461111830194X', '_blank')">
                        View Table in HTML
                    </a><div class="footnote"><p>Abbreviations: ANCOVA, 
analysis of covariance; CI, confidence interval; EQ-5D-3L, EuroQol 
5-Dimensions 3-Levels Questionnaire; EQ VAS, EuroQol visual analogue 
scale; FF/VI, fluticasone furoate/vilanterol; LS, least squares; SE, 
standard error; UC, usual care.</p></div>
<div class="footnote" id="tbl4fna">
<a href="#back-tbl4fna">a</a>Data based on last available on-treatment measurement (Week 52 or early withdrawal visit).</div>
<div class="footnote" id="tbl4fnb">
<a href="#back-tbl4fnb">b</a>Between-group differences (FF/VI <em>versus</em>
 UC), 95% CIs, and p-values were calculated using an ANCOVA model 
adjusted for randomized treatment, asthma maintenance therapy at 
baseline per randomization stratification, ACT total score at baseline 
per randomization stratification, gender, age, and baseline EQ-5D-3L 
utility/VAS score (as appropriate).</div>
<div class="footnote" id="tbl4fnc">
<a href="#back-tbl4fnc">c</a>For
 analysis of the ICS and ICS/LABA subsets of the overall study 
population, the statistical models did not include the asthma 
maintenance therapy at baseline per randomization stratification 
variable.</div>
</div></div>